

### BACKGROUND

Adolescent girls and young women sub-Saharan (AGYW) Africa in are disproportionately affected by HIV, but daily use remains a significant oral PrEP challenge for AGYW

The aim of the study was to qualitatively explore the motivations of South African and Zimbabwean AGYW for starting, stopping and restarting oral PrEP.

# Motivations for starting, stopping and restarting oral PrEP: Experiences of adolescent girls and young women in the HPTN 082 trial

Lisa Mills<sup>1</sup>, Makhosazane N Khoza<sup>1</sup>, Millicent Atujuna<sup>2</sup>, Miria Chitukuta<sup>3</sup>, Fiona Scorgie<sup>1</sup>, Sybil Hosek<sup>4</sup>, Jennifer Velloza<sup>5</sup>, Hlukelo Chauke<sup>1</sup>, Petina Musara<sup>3</sup>, Nomvuyo Mangxilana<sup>2</sup>, Sanele Gumede<sup>1</sup>, Prisca Mutero<sup>3</sup>, Lerato Makhale<sup>1</sup>, Lumka Nobula<sup>2</sup>, Thelma Tauya<sup>3</sup>, Connie Celum<sup>5</sup>, Sinead Delany-Moretlwe<sup>1</sup>

<sup>1</sup>Wits RHI, University of the Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa, <sup>2</sup>Desmond Tutu Health Foundation, Cape Town, South Africa, <sup>3</sup>University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe, <sup>4</sup>Stroger H. Hospital of Cook County, Chicago, IL, USA, <sup>5</sup>University of Washington, Seattle, WA, USA



Living arrangements of AGWY in the sample (n=67)



HIV risk perception frequently motivated adolescent girls and young women to start oral PrEP. Social factors such as stigma and interpersonal support were central in decisions to stop and restart PrEP.

### **METHODS**

- HPTN 082: evaluation of adherence in an open-label study of daily oral PrEP (2016-2018)
- 426 AGYW from Cape Town, Johannesburg, Harare
- 16-25 years, HIV negative, sexually active, and PrEP-eligible
- Randomised to standard support (adherence counselling, weekly SMS reminders, monthly in-person adherence clubs) or standard support plus drug level feedback (PrEP levels tested at week 4 and 8 with 30-minute adherence counselling)

#### **QUALITATIVE SUBSTUDY**

- N=67 qualitative interviews between 2017 and 2018
- Purposive sampling to include adherers, non-adherers, decliners, special cases (adherence based on PrEP drug levels at week 4)
- Interviews were audio-recorded, transcribed and translated into English
- Inductive coding and a thematic approach to analysis was used

# RESULTS

THEME	SUPPORTING QUOTE
<b>HIV risk perception</b> often motivated PrEP start but was less central in AGYW motivations to stop and restart PrEP	"I have been dating one guy and I think he may give me problems. So let me join [the study]. The way I view it, it's for my own safety." (Berenice, 24, Johannesburg).
<b>HIV and PrEP-related stigma</b> (experienced and anticipated) from friends, partners, family, community often motivated skipping doses or pausing PrEP. This included beliefs that PrEP is used by sex workers, 'promiscuous' individuals, sick people, those living with HIV; or that PrEP will cause HIV, weight gain or infertility	"So, when he [husband] saw me taking pills he forbid it he just asked me, that what I have to do with the pills. Then he started to say that 'Maybe you will be doing what, you will be prostituting in Zimbabwe.' Then I just stopped taking the pills." (Tendai, 24, Harare).

**Product characteristics** – anticipated side effects often motivated a delay in PrEP start, and experienced side effects were often linked to a practice of skipping doses. The challenge of a daily regimen and the large pill size often motivated skipping doses

**Interpersonal influence** – peers important in introducing and motivating PrEP uptake. Information and encouragement from clinic staff frequently motivated PrEP restart. AGYW received motivation to restart from peers at retention events. Zimbabwean participants were often motivated to restart after encouragement from a maternal figure

# CONCLUSIONS

- Given stigma at home and AGYW cohabitation with parents, **older** • **generations** should be targeted in interventions to destigmatize AGYW HIV prevention
- Support from **female/maternal figures** could be enhanced with training on sexual health communication with AGYW and female support figures

# **ACKNOWLEDGMENTS**

"Yeah, they used to keep me worried, that you, I will have a headache, I will be this and that, but at the end of the day I said let me test and try them maybe it's not going to be that bad." (Rita, 24, Johannesburg)

"I stopped taking PrEP because he [husband] had said that if I continued taking them it meant that our marriage would be over. That is when I told my grandmother what was happening and then they took him and explained to him. When he had understood that is when I started taking PrEP again." (Iris, 20, Harare).

- **Peers** should be considered for demand creation and adherence support strategy
- Educational materials and information-sharing sessions should include content on prevention-effective adherence - providing an alternative to long-term daily use of PrEP may assist AGYW in effectively using PrEP during seasons of risk and mitigate the challenge associated with daily use.

We thank study participants for trusting us with the information presented here. We are grateful to the teams at the study sites in Johannesburg and Cape Town, South Africa and Harare, Zimbabwe and the HIV Prevention Trials Network that supported data collection and management for this work.

For more information, visit **hptn.org** and follow us: Facebook: **HIVptn** | Twitter: **@HIVptn** | Youtube: **HIVptn**  Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Numbers UM1AI068619-15 (HPTN Leadership and Operations Center), UM1AI068617-15 (HPTN Statistical and Data Management Center), and UM1AI068613-15 (HPTN Laboratory Center).

Presented at AIDS 2022 Montreal, Canada Jul-Aug 2022 Poster Number: EPD339